RNAi drug specialist ADARx raises $446M IPO

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 25 Sept, 00:36 UTC

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.